| Literature DB >> 34943027 |
Anna Freeman1,2, Doriana Cellura1, Magdalena Minnion1, Bernadette O Fernandez1, Cosma Mirella Spalluto1, Denny Levett1,2, Andrew Bates1,2, Timothy Wallis1,2, Alastair Watson1, Sandy Jack1,2, Karl J Staples1,2, Michael P W Grocott1,2, Martin Feelisch1, Tom M A Wilkinson1,2.
Abstract
Redox dysregulation and oxidative stress have been implicated in asthma pathogenesis. Exercise interventions improve symptoms and reduce inflammation in asthma patients, but the underlying mechanisms remain unclear. We hypothesized that a personalised exercise intervention would improve asthma control by reducing lung inflammation through modulation of local and systemic reactive species interactions, thereby increasing antioxidant capacity. We combined deep redox metabolomic profiling with clinical assessment in an exploratory cohort of six female patients with symptomatic asthma and studied their responses to a metabolically targeted exercise intervention over 12 weeks. Plasma antioxidant capacity and circulating nitrite levels increased following the intervention (p = 0.028) and lowered the ratio of reduced to oxidised glutathione (p = 0.029); this was accompanied by improvements in physical fitness (p = 0.046), symptoms scores (p = 0.020), quality of life (p = 0.046), lung function (p = 0.028), airway hyperreactivity (p = 0.043), and eosinophilic inflammation (p = 0.007). Increased physical fitness correlated with improved plasma antioxidant capacity (p = 0.019), peak oxygen uptake and nitrite changes (p = 0.005), the latter also associated with reductions in peripheral blood eosinophil counts (p = 0.038). Thus, increases in "redox resilience" may underpin the clinical benefits of exercise in asthma. An improved understanding of exercise-induced alterations in redox regulation offers opportunities for greater treatment personalisation and identification of new treatment targets.Entities:
Keywords: asthma; exercise; inflammation; oxidative stress; reactive species interactome
Year: 2021 PMID: 34943027 PMCID: PMC8750917 DOI: 10.3390/antiox10121926
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Participant demographics and medications.
| Characteristic | Number (%) or Median [IQR] |
|---|---|
| Female sex | 6 (100) |
| Age (years) | 31.3 ± 10 |
| Never smoker | 5 (83) |
| BMI (kg/m2) | 27.6 [22.26, 30.66] |
| Peripheral blood eosinophil count | 0.25 [0.2, 0.73] |
| FeNO (ppb) | 50.75 [27.25, 93] |
| Co-morbidities | Number (%) |
| Atopy | 5 (83) |
| Anxiety and depression | 2 (33) |
| Urticaria and angioedema | 1 (16%) |
| Anaphylaxis | 1 (16%) |
| Dysfunctional breathing | 1 (16%) |
| Pulmonary Function | Median [IQR] |
| FEV1 % predicted | 89 [78.75, 94.5] |
| FVC % predicted | 100.5 [91.75, 1.3] |
| FEV1/FVC | 77 [73.75, 82.25] |
| FEF 25–75 % predicted | 68.5 [31.30, 85.25] |
| % change FEV1 post BD | 5 [3, 13.25] |
| Asthma Medication | Number (%) or mean ± SD |
| on ICS | 4 (66%) |
| ICS dose (BDP equivalent µg/day) | 483 ± 371 |
| on LABA | 2 |
| LABA dose (formoterol equivalent µg/day) | 7.2 ± 10.73 |
| on Montelukast | 1 (16%) |
Presented as number and percentage, or median and IQR. Abbreviations: BD: bronchodilator; BDP: beclomethasone dipropionate; BMI: body mass index; FEF 25–75: mid-expiratory flow rate FeNO: fractional exhaled nitric oxide; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; ICS: inhaled corticosteroid; LABA: long-acting bronchodilator.
Body composition and aerobic capacity.
| Variables | Baseline | Post Intervention | |
|---|---|---|---|
| Anthropometric Values | |||
| BMI | 27.7 (22.3, 30.7) | 27.6 (22, 29.6) | 0.136 |
| Fat-free mass (%) | 62.9 (58.3, 67.5) | 60.7 (56.2, 67.5) | 1 |
| Fat mass (%) | 36.6 (32.5, 41.7) | 36.8 (32.5, 42.1) | 0.528 |
| Visceral Adipose Tissue (litres) | 0.83 (0.45, 1.23) | 0.74 (0.16, 1) | 0.465 |
| Skeletal Muscle Mass (kg) | 23 (18.8, 27.2) | 23 (18.3, 27.2) | 0.463 |
| Aerobic Capacity | |||
| VO2 peak (mL/kg/min) | 21.6 (19, 28) | 25 (20, 31.5) | 0.058 * |
| Anaerobic Threshold (mL/kg/min) | 10.4 (9.4, 14) | 12.6 (10, 15.6) | 0.046 * |
* = statistically significant as assessed by Wilcoxon signed rank test. Abbreviations: BMI: body mass index; IQR: interquartile range; n.d: not determined; VO2 peak: maximal oxygen uptake.
Symptom scores and quality of life scores between baseline and week 12.
| Variable | Baseline | Post 12-Week Intervention | |
|---|---|---|---|
| ACQ 6 Score | 2 (1.8, 2.6) | 1.2 (0.8, 1.5) | 0.028 * |
| AQLQ Total Score | 4.8 (4.1, 5.3) | 5.8 (5.5, 6.3) | 0.046 * |
| AQLQ Symptoms Domain | 4.5 (3.8, 5) | 5.8, 5.1, 6.3) | 0.046 * |
| AQLQ Activity Domain | 5.3 (4.4, 6) | 6.1 5.7, 6.8) | 0.116 |
| AQLQ Emotions Domain | 4.8 (2.7, 5.3) | 6.1 (5.3, 6.5) | 0.027 * |
| AQLQ Environmental Domain | 4.5 (3.6, 5.4) | 5.6 (4.9, 6.6) | 0.043 * |
Statistical assessment by Wilcoxon signed rank test, for (ACQ 6 Score) asthma control questionnaire, (AQLQ Total Score) asthma quality of life questionnaire, (AQLQ Symptoms Domain) asthma quality of life questionnaire symptom domain, (AQLQ Activity Domain) asthma quality of life activity domain, (AQLQ Emotions Domain) asthma quality of life emotional domain, and (AQLQ Environmental Domain) asthma quality of life questionnaire environmental domain. * = statistically significant median and IQR for each patient. IQR: interquartile range.
Assessment of inflammation.
| Variables | Baseline | Post Intervention | |
|---|---|---|---|
| Airway Inflammation | |||
| FeNO (ppb) | 50 (27, 93) | 35 (19, 94) | 0.753 |
| Clinical inflammatory markers | |||
| WCC × 109/L | 7.2 (5.6, 9.1) | 6.7 (4.0, 7.5) | 0.046 * |
| Neutrophils × 109/L | 6.7 (2.7, 5.8) | 3.9 (1.9, 4.6) | 0.054 |
| Eosinophils × 109/L | 0.25 (0.2, 0.73) | 0.2 (0.18, 0.43) | 0.007 * |
| Lymphocytes × 109/L | 2.2 (1.6, 2.7) | 1.8 (1.7, 2.2) | 0.049 * |
| Monocytes × 109/L | 0.5 (0.38, 0.55) | 0.45 (0.45, 0.53) | 0.414 |
| CRP mg/L | 3 (1.5, 6.3) | 1 (0.75, 6.8) | 0.340 |
| Cytokines (pg/mL) | |||
| CCL11/eotaxin | 173.0 (138.5, 214.0) | 153.97 (134.0, 180.1) | 0.046 * |
| IL-5 | 7.24 (6.39, 10.33) | 5.34 (4.04, 7.37) | 0.046 * |
| TNFα | 15.63 (9.75, 15.63) | 9.96 (5.19, 12.53) | 0.046 * |
| IFNγ | 17.89 (10.87, 20.32) | 11.9 (7.48, 12.91) | 0.046 * |
| IL1-ra | 644.3 (328.0, 1077.8) | 469.9 (307.1, 900.8) | 0.116 |
| IL-6 | 8.32 (6.35, 12.48) | 6.60 (5.40, 8.74) | 0.115 |
| IL-10 | 79.20 (65.89, 96.72) | 72.92 (58.80, 78.7) | 0.173 |
| IL-13 | 66. 81 (58.95, 76.23) | 55.72 (48.70, 64.85) | 0.141 |
Statistical assessment by Wilcoxon or Friedman test, * = statistically significant. Abbreviations: IQR: interquartile range; CRP: C reactive protein; IFN: interferon; IL: interleukin; pg/mL; picograms/millilitre; TNF: tumour necrosis factor; WCC: white cell count.
Figure 1Changes in pattern of responses of the free thiol metabolome (A–J). Data presented for n = 6 before and after acute physiological challenge of a cardiopulmonary exercise test, presented as mean and SEM, with overlaid individual data (circles, squares, up- and downward triangles). Data presented in nM or concentration ratio. Green bars = baseline, orange bars = week 3, blue bars = week 6 and grey bars = week 12. Abbreviations: GSH: reduced gluthathione; GSSG: oxidised glutathione; Cys: cysteine, CySS: cystine; HCys: homocysteine, HCySS: homocystine, * = p < 0.05.
Figure 2Pattern of response to changes in concentration of total and bound thiols in plasma (A–H). Data presented for before and after acute physiological challenge of a cardiopulmonary exercise test at each sampling point throughout the training intervention, presented as mean and SEM, with overlaid individual data (circles, squares and triangles; for the sake of direct comparison to free thiols, all concentrations are presented in [nM]). Green bars = baseline, orange bars = week 3, blue bars = week 6, and grey bars = week 12. Abbreviations: GSH: gluthathione; Cys: cysteine; HCys: homocysteine, * = p < 0.05.
Figure 3Pattern of redox responses to pre- and post-acute exercise challenge at each sampling point in study for plasma concentrations of nitrite (A), nitrate (B), nitroso species (C), TBARS (D) and FRAP (E), presented as mean and SEM, with individual data (circles, squares and triangles) overlaid. Data presented in µM or nM. Green bars = baseline, orange bars = week 3, blue bars = week 6, grey bars = week 12. Abbreviations: CPET: cardiopulmonary exercise test; RXNO: total nitroso species; TBARS: thiobarbituric acid reactive substances; FRAP: ferric reducing ability of plasma. * = p < 0.05.
Figure 4Significant correlations (Spearman’s rho correlation) between improvements in physical fitness, increased redox capacity and inflammation. (A) A greater increase in maximum oxygen uptake is associated with a greater increase in pre-CPET nitrite from baseline (r = 0.943, p = 0.019), (B) a greater increase in oxygen uptake at AT strongly correlates with a larger increase in FRAP (r = 0.886, p = 0.019), and (C) a greater increase in pre-CPET nitrite significantly correlates with a greater reduction in peripheral blood eosinophil levels (r = −0.837, p = 0.038). Abbreviations AT: (oxygen uptake at) anaerobic threshold; FRAP: ferric reducing ability of plasma.